Incidence of chronic obstructive pulmonary disease in people with HIV in Ontario, 1996-2015: a retrospective population-based cohort study.


Journal

CMAJ open
ISSN: 2291-0026
Titre abrégé: CMAJ Open
Pays: Canada
ID NLM: 101620603

Informations de publication

Date de publication:
Historique:
entrez: 20 2 2020
pubmed: 20 2 2020
medline: 20 2 2020
Statut: epublish

Résumé

Because of high smoking rates and HIV-related factors, people with HIV may be at high risk for chronic obstructive pulmonary disease (COPD); however, population-based estimates of the incidence of COPD among people with HIV are lacking, particularly for women. We compared the incidence of COPD among Ontario adults aged 35 years or more with and without HIV between Jan. 1, 1996, and Dec. 31, 2015. We conducted a population-based study using Ontario's health administrative databases. We compared the incidence of COPD between people with and without HIV using standardized incidence ratios and generalized estimating equations with a log link function. We identified 1849 people with HIV and 1 168 727 HIV-negative people who were newly diagnosed with COPD between 1996 and 2015. People with HIV were younger than HIV-negative people (mean age 49.7 [standard deviation 10.4] yr v. 62.2 [standard deviation 14.8] yr; standardized difference 0.98). Rates of COPD were higher among people with HIV than among HIV-negative people (10.4 v. 9.0 cases per 1000 person-years; standardized incidence ratio 1.16, 95% confidence interval [CI] 1.10 to 1.21; adjusted rate ratio 1.34, 95% CI 1.27 to 1.41). In sex-stratified analyses, rates of COPD were higher among men with HIV (adjusted rate ratio 1.32, 95% CI 1.24 to 1.40) and women with HIV (adjusted rate ratio 1.54, 95% CI 1.37 to 1.72) than among men and women without HIV. In a sensitivity analysis, smoking explained observed differences in COPD incidence. People with HIV had higher rates of incident COPD than HIV-negative people. This may reflect the disproportionately higher prevalence of smoking among the former.

Sections du résumé

BACKGROUND
Because of high smoking rates and HIV-related factors, people with HIV may be at high risk for chronic obstructive pulmonary disease (COPD); however, population-based estimates of the incidence of COPD among people with HIV are lacking, particularly for women. We compared the incidence of COPD among Ontario adults aged 35 years or more with and without HIV between Jan. 1, 1996, and Dec. 31, 2015.
METHODS
We conducted a population-based study using Ontario's health administrative databases. We compared the incidence of COPD between people with and without HIV using standardized incidence ratios and generalized estimating equations with a log link function.
RESULTS
We identified 1849 people with HIV and 1 168 727 HIV-negative people who were newly diagnosed with COPD between 1996 and 2015. People with HIV were younger than HIV-negative people (mean age 49.7 [standard deviation 10.4] yr v. 62.2 [standard deviation 14.8] yr; standardized difference 0.98). Rates of COPD were higher among people with HIV than among HIV-negative people (10.4 v. 9.0 cases per 1000 person-years; standardized incidence ratio 1.16, 95% confidence interval [CI] 1.10 to 1.21; adjusted rate ratio 1.34, 95% CI 1.27 to 1.41). In sex-stratified analyses, rates of COPD were higher among men with HIV (adjusted rate ratio 1.32, 95% CI 1.24 to 1.40) and women with HIV (adjusted rate ratio 1.54, 95% CI 1.37 to 1.72) than among men and women without HIV. In a sensitivity analysis, smoking explained observed differences in COPD incidence.
INTERPRETATION
People with HIV had higher rates of incident COPD than HIV-negative people. This may reflect the disproportionately higher prevalence of smoking among the former.

Identifiants

pubmed: 32071142
pii: 8/1/E83
doi: 10.9778/cmajo.20190028
pmc: PMC7028164
doi:

Types de publication

Historical Article Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

E83-E89

Informations de copyright

Copyright 2020, Joule Inc. or its licensors.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

PLoS One. 2016 Aug 15;11(8):e0160460
pubmed: 27525413
Am J Respir Crit Care Med. 2014 Oct 1;190(7):744-55
pubmed: 25137293
IARC Sci Publ. 1987;(82):1-406
pubmed: 3329634
Cochrane Database Syst Rev. 2016 Jun 13;(6):CD011120
pubmed: 27292836
Lancet Glob Health. 2018 Feb;6(2):e193-e202
pubmed: 29254748
AIDS. 2015 Aug 24;29(13):1691-700
pubmed: 26372280
Stat Med. 2007 Feb 20;26(4):734-53
pubmed: 16708349
J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):e10-9
pubmed: 26322672
PLoS Med. 2006 Nov;3(11):e442
pubmed: 17132052
J Infect Chemother. 2014 Jun;20(6):361-4
pubmed: 24661405
PLoS One. 2011;6(6):e21748
pubmed: 21738786
Infection. 2013 Apr;41(2):347-53
pubmed: 22971938
Nicotine Tob Res. 2016 Dec;18(12):2177-2184
pubmed: 27245237
Thorax. 2015 Feb;70(2):121-6
pubmed: 25428609
Biometrics. 2001 Mar;57(1):120-5
pubmed: 11252586
AIDS Patient Care STDS. 2017 Feb;31(2):49-59
pubmed: 28170303
Am J Respir Crit Care Med. 2013 Mar 15;187(6):596-601
pubmed: 23328526
Chest. 2006 Nov;130(5):1326-33
pubmed: 17099007
J Infect Dis. 2016 Dec 1;214(11):1672-1681
pubmed: 27815384
HIV Med. 2014 Jul;15(6):321-9
pubmed: 24314004
AIDS. 2004 Mar 26;18(5):793-8
pubmed: 15075515
Clin Infect Dis. 2011 Dec;53(11):1120-6
pubmed: 21998278
Am J Respir Crit Care Med. 2011 Feb 1;183(3):388-95
pubmed: 20851926
Am J Respir Crit Care Med. 2019 Apr 15;199(8):961-969
pubmed: 30384774
Am J Respir Crit Care Med. 2013 May 15;187(10):1110-7
pubmed: 23392441
Am J Respir Crit Care Med. 2010 Sep 1;182(5):693-718
pubmed: 20802169
BMC Infect Dis. 2017 Feb 27;17(1):174
pubmed: 28241797
Clin Infect Dis. 2014 Jul 15;59(2):287-97
pubmed: 24771333
PLoS One. 2019 Jan 4;14(1):e0210096
pubmed: 30608962
BMJ. 2009 Jan 26;338:a3172
pubmed: 19171560
AIDS. 2016 Jan 28;30(3):455-63
pubmed: 26765938
PLoS One. 2017 Jan 5;12(1):e0169359
pubmed: 28056048
AIDS Behav. 2019 Jan;23(1):152-160
pubmed: 30088200
CMAJ Open. 2016 May 25;4(2):E240-8
pubmed: 27398370
Lancet Respir Med. 2016 Dec;4(12):980-989
pubmed: 27773665
Ann Intern Med. 2015 Mar 3;162(5):335-44
pubmed: 25732274
Am J Respir Crit Care Med. 1999 May;159(5 Pt 1):1439-44
pubmed: 10228108
Clin Infect Dis. 2014 Dec 15;59(12):1787-97
pubmed: 25182245
COPD. 2009 Oct;6(5):388-94
pubmed: 19863368

Auteurs

Tony Antoniou (T)

ICES (Antoniou, Yao, Gershon); Department of Family and Community Medicine (Antoniou), Li Ka Shing Knowledge Institute, St. Michael's Hospital and University of Toronto; Toronto General Hospital Research Institute (Raboud); Dalla Lana School of Public Health (Raboud), University of Toronto; Department of Medicine (Gershon), Sunnybrook Health Sciences Centre, Toronto, Ont. tantoniou@smh.ca.

Zhan Yao (Z)

ICES (Antoniou, Yao, Gershon); Department of Family and Community Medicine (Antoniou), Li Ka Shing Knowledge Institute, St. Michael's Hospital and University of Toronto; Toronto General Hospital Research Institute (Raboud); Dalla Lana School of Public Health (Raboud), University of Toronto; Department of Medicine (Gershon), Sunnybrook Health Sciences Centre, Toronto, Ont.

Janet Raboud (J)

ICES (Antoniou, Yao, Gershon); Department of Family and Community Medicine (Antoniou), Li Ka Shing Knowledge Institute, St. Michael's Hospital and University of Toronto; Toronto General Hospital Research Institute (Raboud); Dalla Lana School of Public Health (Raboud), University of Toronto; Department of Medicine (Gershon), Sunnybrook Health Sciences Centre, Toronto, Ont.

Andrea S Gershon (AS)

ICES (Antoniou, Yao, Gershon); Department of Family and Community Medicine (Antoniou), Li Ka Shing Knowledge Institute, St. Michael's Hospital and University of Toronto; Toronto General Hospital Research Institute (Raboud); Dalla Lana School of Public Health (Raboud), University of Toronto; Department of Medicine (Gershon), Sunnybrook Health Sciences Centre, Toronto, Ont.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH